10 independently detected trends connected to this subject, with the latest coverage first.
This hub groups 10 separate news trends connected to Car‑T, spanning August 18, 2026 through October 24, 2026. Each event page combines source coverage, attention velocity and a time-stamped explanation instead of treating every headline as a separate story.
The record below represents 75 article observations and 74 source signals, led by Business, Health coverage. Use it to compare how individual events emerged, spread and changed over time.
A fatal infection in Bristol Myers’ autoimmune CAR‑T trial upends expectations for a promising multiple‑sclerosis therapy
5 news sources are covering this Business story right now — Archynetys is tracking how fast it spreads.
CAR T and bispecifics revolutionize blood cancer treatment
7 news sources are covering this Business story right now — Archynetys is tracking how fast it spreads.
14 news sources are covering this Health story right now — Archynetys is tracking how fast it spreads.
Bristol Myers' blood cancer cell therapy achieves key milestone in mid-stage trial
Personalized mRNA cancer vaccines spark a biotech gold rush, drawing investors and reshaping oncology treatment.
Novartis and Bristol Myers have halted autoimmune CAR-T trials after three patient deaths.
A cancer therapy has shown promise in treating severe rheumatoid arthritis, offering new hope to patients.
A third death in China's gene therapy trials raises questions about the safety and oversight of these experimental treatments.